@article{TLCR29280,
author = {Jennifer W. Carlisle and Suresh S. Ramalingam},
title = {Improving outcomes for brain metastases in EGFR mutated NSCLC},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {Suppl 4},
year = {2019},
keywords = {},
abstract = {Tyrosine kinase inhibitors (TKIs) of activating epidermal growth factor receptor (EGFR) mutations have revolutionized the care of patients with advanced non-small cell lung cancer (NSCLC) who harbor a targetable EGFR mutation. Compared to platinum doublet chemotherapy, median overall survival (OS) has improved from a historical 8–12 months with chemotherapy alone (1) to 26 months with first generation EGFR TKIs gefitinib and erlotinib (2).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/29280}
}